RADIONETICS ONCOLOGY
Radionetics Oncology is a pharmaceutical company focused on the discovery and development of novel radiotherapeutics for the treatment of a wide range of oncology indications, is poised to capitalize on the increasing demand for novel radiotherapeutics.
RADIONETICS ONCOLOGY
Social Links:
Industry:
Pharmaceutical Therapeutics
Founded:
2021-01-01
Address:
California City, California, United States
Country:
United States
Status:
Active
Total Funding:
30 M USD
Similar Organizations
1859
1859 is a biotechnology company focusing on the discovery and development of next-generation therapeutics.
Crinetics Pharmaceuticals
Crinetics is a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics.
Edgewise Therapeutics
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization.
Gossamer Bio
Gossamer Bio is a biopharmaceutical company focused on the discovery and development of novel and differentiated therapeutic products.
Santi Therapeutics
Santi Therapeutics is a pharmaceutical company that focuses on the research and development of small molecule therapeutics.
Vetsource
Vetsource provides comprehensive solutions to those who care for pets - veterinarians and pet owners.
Current Advisors List
Current Employees Featured
Founder
Investors List
Frazier Healthcare Partners
Frazier Healthcare Partners investment in Private Equity Round - Radionetics Oncology
5AM Ventures
5AM Ventures investment in Private Equity Round - Radionetics Oncology
Key Employee Changes
| Date | New article |
|---|---|
| 2022-04-12 | Radionetics Oncology Appoints Nishan de Silva, M.D. as Chief Executive Officer |
More informations about "Radionetics Oncology"
Radionetics Oncology Enters Into Strategic Agreement With Lilly
SAN DIEGO, CA - JULY 1, 2024 - Radionetics Oncology a biotechnology company discovering and developing novel small molecule G protein coupled receptor (GPCR) targeted …See details»
Radionetics Oncology - Crunchbase Company Profile
Radionetics Oncology may be growing as it has successfully raised a significant amount of capital, specifically $52.5 million in a Series A funding round, which …See details»
Radionetics Oncology Raises $52.5 Million Series A to Advance …
SAN DIEGO, January 3, 2024 – Radionetics Oncology, Inc., a clinical stage radiopharmaceutical company focused on the discovery and development of novel agents for the treatment of a …See details»
Radionetics Oncology Emerges from Crinetics …
Radionetics Oncology, a pharmaceutical company focused on the discovery and development of novel radiotherapeutics for the treatment of a wide range of oncology indications, is poised to capitalize on the increasing demand for …See details»
Radionetics Oncology - DCVC
Radionetics Oncology. Discovering more precise ways to deploy radiopharmaceuticals against solid tumors. View Website. First Investment: 2023 Follow us on linkedin; ... And that’s exactly what Radionetics is doing: the company’s knowledge of GPCR biology and small-molecular medicinal chemistry allows it to discover and develop ...See details»
Radionetics Oncology - The Org
Radionetics Oncology is a pharmaceutical company focused on the discovery and development of novel radiotherapeutics for the treatment of a wide range of oncology indications. The …See details»
Radionetics Oncology Emerges from Crinetics Pharmaceuticals
Oct 18, 2021 Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel nonpeptide …See details»
Series A - Radionetics Oncology - 2023-08-14 - Crunchbase
Aug 14, 2023 Radionetics Oncology raised $52500000 on 2023-08-14 in Series A. Search Crunchbase. Start Free Trial . Chrome Extension. Solutions. Products. Resources. Pricing. Resources. Log In. Funding Round. Series A - Radionetics Oncology . Save . Summary. Overview. Edit Overview Section. Organization Name . Radionetics Oncology . Announced …See details»
Radionetics Oncology 2025 Company Profile: …
5AM Ventures, Crinetics Pharmaceuticals, DCVC Bio, Frazier Healthcare Partners, and GordonMD Global Investments have invested in Radionetics Oncology. Who are Radionetics Oncology’s competitors? NexImmune , …See details»
Radionetics Oncology - Products, Competitors, Financials, …
Radionetics Oncology is a pharmaceutical company specializing in precision radiopharmaceuticals for the oncology sector. The company's main offerings include targeted small molecule radiopharmaceuticals that deliver radiation directly to tumors, leveraging their expertise in drug discovery and development to create new cancer treatments.See details»
Lilly builds in radiopharma with $140m Radionetics deal
Jul 2, 2024 Meanwhile, in May, Lilly paid $60 million upfront to use Aktis Oncology's technology to generate radiopharma candidates for solid tumours in a deal that could be worth up to $1.1 billion.See details»
Radionetics Oncology - Company Profile
Radionetics Oncology is a pharmaceutical company focused on the discovery and development of novel radiotherapeutics for the treatment of a wide range of oncology indications. The …See details»
Radionetics Oncology Closes $52.5M Series A | citybiz
Jan 4, 2024 Radionetics Oncology, a San Diego, CA-based clinical stage radiopharmaceutical company focused on the discovery and development of novel agents for the treatment of a wide range of oncology indications, raised $52.5M in Series A funding.. The round, which brought the total amount to $82.5M, was led by Frazier Life Sciences, 5AM Ventures, and new investor, …See details»
Radionetics Oncology Raises $52.5 Million Series A to Advance …
Jan 3, 2024 Radionetics Oncology, Inc. is a clinical stage radiopharmaceutical company focused on the discovery and development of novel radiotherapeutics for the treatment of a wide range …See details»
Radionetics Oncology - Contacts, Employees, Board Members
Radionetics Oncology is a pharmaceutical company that focuses on the discovery and development of novel radiotherapeutics. ... Experience the new Crunchbase, powered by AI . …See details»
Brett Ewald, Ph.D. | Radionetics
Jul 1, 2024 Brett Ewald, Ph.D., is a founding member of Radionetics and serves as Chief Operating Officer. He has 20 years of oncology experience and has led corporate strategy, …See details»
Eli Lilly & Co. Options Radionetics for $1B
Jul 8, 2024 SAN DIEGO – Radionetics Oncology officially has a suitor. The Torrey Pines-based biotech announced July 1 a strategic relationship with Eli Lilly and Company (NYSE: LLY) that gives the pharma giant exclusive rights to acquire Radionetics for $1 billion. The agreement also includes a $140 million upfront cash payment to Radionetics that will help fund […]See details»
Chetan Lathia - Radionetics Oncology - LinkedIn
I am a dynamic biotechnology executive with a proven track record of leading drug… · Experience: Radionetics Oncology · Education: L.M. College of Pharmacy · Location: New …See details»
Radionetics Oncology: $52.5 Million Secured To Advance ...
Jan 4, 2024 Radionetics Oncology - a clinical-stage radiopharmaceutical company focused on discovering and developing novel agents for treating a wide range of oncology indications - recently announced the completion of a $52.5 million Series A financing. The funding round was led by Frazier Life Sciences, 5AM Ventures, and new investor, DCVC Bio, with participation …See details»
Radionetics Oncology - Funding, Financials, Valuation & Investors
Radionetics Oncology is a pharmaceutical company that focuses on the discovery and development of novel radiotherapeutics. New. Resources. Advanced Search. ... How much …See details»